← Back to Search

Treatment Arm for Peripheral Arterial Disease (Evol-PAD Trial)

Phase 4
Waitlist Available
Led By Leonardo Clavijo, MD, PhD
Research Sponsored by Leonardo Clavijo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six months
Awards & highlights

Evol-PAD Trial Summary

This trial will show if adding a PCSK-9 inhibitor to statin therapy can improve quality of life for patients with peripheral arterial disease by reducing pain, improving walking ability, and increasing blood flow to the extremities.

Eligible Conditions
  • Peripheral Arterial Disease

Evol-PAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evolocumab effect in pain free walking time (PFWT) in patients with PAD
Secondary outcome measures
Evolocumab effect in maximal walking time (MWT) in patients with PAD
Other outcome measures
Evolocumab effect in brachial endothelial function by changes in Flow Mediated Dilation (FMD).
Evolocumab effect in lower extremity arterial perfusion in ankle-brachial indices (ABI).
Evolocumab effect in lower extremity arterial perfusion in transcutaneous oxygen changes.
+4 more

Side effects data

From 2020 Phase 4 trial • 259 Patients • NCT03096288
5%
chest pain
5%
gastrointestinal bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
HPR - Evolocumab
HPR - Placebo
NPR - Evolocumab
NPR - Placebo

Evol-PAD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment ArmExperimental Treatment1 Intervention
43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of evolocumab 420 mg via subcutaneous injections for 6 months.
Group II: Control ArmPlacebo Group1 Intervention
43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of placebo via subcutaneous injections for 6 months.

Find a Location

Who is running the clinical trial?

Leonardo ClavijoLead Sponsor
2 Previous Clinical Trials
132 Total Patients Enrolled
AmgenIndustry Sponsor
1,371 Previous Clinical Trials
1,378,020 Total Patients Enrolled
Leonardo Clavijo, MD, PhD2.73 ReviewsPrincipal Investigator - University of Southern California
University of Southern California
4 Previous Clinical Trials
285 Total Patients Enrolled
2Patient Review
At first, I was content with the care I was receiving from Dr. Clavijo. My chest pain symptoms, however, persisted. The doctor then became very dismissive, attributing my symptoms to anxiety. Despite telling me that women's heart symptoms frequently present differently than men's, no diagnostics were done other than those routinely performed on male patients. When I saw him for a follow up visit due to my symptoms becoming more frequent and a little more severe, he brushed them off as anxiety and told me to address the real issue by seeing a psychiatrist, psychologist, and taking meds. He was very dismissive and gave the impression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease
Leonardo Clavijo 2017. "Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04306081.
All > Pad
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top